Protocol Ledger

NCT03570697 · Phase III · COMPLETED

Imaging of Coronary Plaques in Participants Treated With Evolocumab

Interventional Phase III clinical trial protocol NCT03570697 sponsored by Amgen in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-19 Enrollment: 164 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03570697
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)164 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03570697
Protocol FieldVerified Registry Value
NCT IdentifierNCT03570697
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment164 participants (ACTUAL)
Registered Start Date2018-11-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03570697
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
University Hospitals Cleveland Medical CenterCleveland, OHOpen Hospital Dossier ->
Royal Prince Alfred HospitalCamperdown, AustraliaOpen Hospital Dossier ->
Royal North Shore HospitalSt Leonards, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI